GILD vs BIIB
GILD and BIIB side by side — valuation & fundamentals (public data).
Key statistics
| Metric | GILDGILEAD SCIENCES, INC. | BIIBBIOGEN INC. |
|---|---|---|
| Market cap | $164.76B | $30.88B |
| P/E (TTM) | 18.1 | 22.5 |
| P/B | 7.01 | 2.09 |
| P/S | 5.6x | 3.1x |
| Dividend yield | 2.43% | — |
| Revenue | $29.74B(TTM) | $9.94B(TTM) |
| Revenue growth (YoY) | 2.4% | 2.2% |
| Net income | $9.22B(TTM) | $1.37B(TTM) |
| Earnings growth (YoY) | 1672.9% | -20.8% |
| EPS, diluted | $7.35(TTM) | $9.30(TTM) |
| EBIT margin | 34.0% | 28.7% |
| ROE | 36.2% | 8.7% |
| ROIC | 21.6% | 13.0% |
| Piotroski F | — | 4/9 |
| 1y total return | +19.0% | +63.5% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: GILD vs BIIB
| Metric | GILD | BIIB |
|---|---|---|
| End value | $20.6K | $8.3K |
| Total return | +105.7% | -16.9% |
| CAGR | +7.2% | -1.8% |
| Volatility | 25.7% | 41.4% |
| Sharpe | 0.25 | 0.06 |
| Sortino | 0.37 | 0.10 |
| Max drawdown | -36.0% | -72.7% |
Based on 2600 common trading days, 2016-03-28 → 2026-07-29 · risk-free 3.83% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)